Comparing cancer mortality and GDP health expenditure in England and Wales with other major developed countries from 1979 to 2006

British Journal of Cancer

Volumn 105, Issue 11, 2011, Pages 1788-1794

  Pritchard, C ^a   Hickish, T ^a,b  

^a BOURNEMOUTH UNIVERSITY   (United Kingdom)

^b ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

age; comparison; deaths; international

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CANADA; CANCER INCIDENCE; CANCER MORTALITY; COMPARATIVE STUDY; DEVELOPED COUNTRY; ECONOMIC EVALUATION; FEMALE; FRANCE; GERMANY; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HUMAN; ITALY; JAPAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; SEX DIFFERENCE; SPAIN; UNITED KINGDOM; UNITED STATES;

ADOLESCENT; ADULT; AGED; DEVELOPED COUNTRIES; ENGLAND; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; WALES; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 81955164834     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.393     Document Type: Article

References (53)

1. Albano JD, Ward E, Ahmedian J, Jemal A, Cokkindes VE, Murray T, Henley J, Liff J, Thun MJ (2007) Cancer mortality in the United States by education level and race. J Nat Cancer Inst 99: 1385-1394
2. Appleby J (2011) Does poor health justify NHS reform? BMJ 342: 566
3. Autier P, Boniol M (2011) Caution needed for country specific cancers survival. Lancet 377: 99-101
4. Berrino F, De Angelis S, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M, EUROCARE Working group (2007) Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of EUROCARE-4 study. Lancet Oncol 8: 773-783 (Pubitemid 47321600)
5. Bosetti C, Malvezzi M, Chatenoud L, Negri E, Levi F, La Vecchia C (2005) Trends in cancer mortality in the Americas 1970-2000. Ann Oncol 16: 489-511 (Pubitemid 40458329)
6. Buxton MJ (2006) Economic evaluation and decision making in the UK. Pharmacoeconomics 24: 11333-11342
7. Coleman MP, Forman D, Bryant J, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA, ICBP Module 1 Working Group (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377: 127-138
8. Craft A, Pritchard-Jones K (2007) UK childhood cancer survival falling behind the rest of the EU? Lancet Oncology 8: 662-663 (Pubitemid 47163578)
9. Cutler DM, Rosen AB, Vijan S (2006) The value of medical spending in the US 1960-2000. N England J Med 355: 920-927
10. D.o.H. (2006a) Implementing the NHS Cancer Plan. Department of Health: London D.o.H. (2006b) Governmental Expenditure Plans: Departmental Report. Department of Health, HMSO: London
11. D.o.H. (2011) Improving Outcomes: A strategy for Cancer. Department of Health: London
12. Drummond MF, Mason AR (2007) European perspectives on the costs and cost-effectiveness of cancer therapies. J Clinic Oncol 25: 191-195 (Pubitemid 350003033)
13. Faden RR, Chalkidou K, Applby J, Waters HR, Leider J (2009) Expensive cancer drugs: a comparison between the United States and the United Kingdom. Milbank Qy 87: 789-819
14. Gladen BC, Edfeldt AW (1988) On graphing rate ratios. Am J Epidem 118: 905-908
15. Kelley E (2007) Health, spending and the effort to improve quality in OECD countries: a review of the data. JR Soc Promot Health 127: 64-71 (Pubitemid 46322770)
16. Luce BR, Maukopf J, Sloan FA, Ostermann J, Paramore LC (2006) The return on investment in health care. Value Health 9: 146-156
17. Lyratzopoulus G, Berbiere JM, Rachet B, Baum M, Thompson MR, Coleman MP (2011) Changes over time in socio-inequalities in breast and rectal cancer survival in England and Wales during a 32 year period (1973-2004): the potential role of health care. Ann Oncol 22: 1661-1666
18. OECD (2010) Health at a Glance 2010. http://www.oecd.org:80/health/
19. ONS (2011) Cancer Statistics: Registration: Registrations of Cancer Diagnosed in 1992-2008; England. Office of National Statistics: London, MBI Series 21-37; www.statistics.gov.uk
20. Pritchard C, Lindsay K, Cox M, Foulkes L (2011) Re-evaluating the National Subarachnoid Haemorrhage study (2006) from a patientrelated-outcome- measure perspective: comparing fiscal outcomes of treatment-as-usual with an enhanced service. Brit J Neurosurg 25: 376-383
21. Pritchard C, Evans B (1996) Comparison of cancer deaths in England & Wales and the developed world by age and gender 1973-1992, and, new malignancies in England & Wales 1971-1988. Public Health 110: 49-59
22. Pritchard C, Hickish T (2008) Changes in cancer incidence & mortality in England & Wales and cancer deaths compared with the major developed countries 1979-2002 within context of GDP expenditure on health. European Institute of Oncology. E Cancer Med Sci 2: 1-18
23. Pritchard C, Hickish T (2011) Cancer survival in Australia, Canada, Norway, Sweden and the UK. Lancet 377: 1149
24. Rachet B, Ellis L, Maringe C, Chu T, Nur U, Quaresma M, Shah A, Walters S, Woods L, Forman D, Coleman MP (2010) Socioeconomic inequalities in cancer survival in England after the NHS cancer plan. Br J Cancer 103: 446-453
25. Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, Ellis L, Walters S, Forman D, Steward J, Coleman MP (2009) Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol 10: 351-369
26. Richards M (2009) Assessment of the NHS cancer plan in England. Lancet Oncol 10: 311
27. Roland M, Rosen R (2011) England's NHS embarks upon controversial and risky market style reforms in health care. New Engl J Med 364: 1360-1366
28. Short PF, Moran JR, Punekar R (2011) Medical expenditures of adult cancer survivors aged o65 years in the United States. Cancer 15: 2791-2800
29. Sikora K (2009) Was the NHS cancer plan worth the effort? Lancet Oncol 10: 312
30. Sloggett A, Young H, Grundy E (2007) The association of cancer survival with four socio-economic indicators: a longitudinal study of the older population of England & Wales 1981-2000. BMC Cancer 25: 20-24
31. US Bureau of Statistics (2010) Annual Statistics of the United States: International Comparison. US Bureau of Statistics: Washington, DC
32. USDHHS (2005) Comparability of Cause of Death Between ICD-9 and ICD-10: Preliminary Estimates. National Statistics Centre; US Department of Health & Human Services: Washington DC, National Vital Statistics Report No 49
33. USNCHS (2004) Health, United States. US National Centre for Health Statistics: Washington, DC
34. USNCHS (2010) USA Health Statstics 2009. US National Centre for Health Statstics: Washington, DC.
35. Wegwarth O, Gaissmaier W, Gigerenzer G (2011) Deceiving numbers: survival rates and their impact upon Doctors communication. Med Decis Making 31(3): 386-394
36. WHO (1992) International Classification of Disease, 10th Edition. Geneva, World Health Organisation.
37. WHO (2008) World Statistics Annual, http://www.who.int/entity/whosis/ whostat/EN-WHS08-Full.pdf
38. Wilking N (2009) A Review of Breast Cancer Care and Treatment in 18 Countries in Europe, Asian and Latin America Comparator Report Karolinska Institute: Stockholm, Sweden
39. Wilking N, Jonsson B, Hogberg D, Justo N (2009) Patient Access to Cancer Drugs in Europe Comparator Report Karolinska Institute: Stockholm, Sweden 1693-1696
40. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28: 949-954
41. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S (2011) Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol; e-pub ahead of print 16 March 2011
42. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779-4786 (Pubitemid 350086481)
43. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson 3rd AB (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544 (Pubitemid 46733080)
44. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342 (Pubitemid 38702844)
45. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508
46. Iqbal K, Chu Q, Mei Q, Chen Y (2007) Bevacizumab-associated reversible hypotension. Clin Oncol (R Coll Radiol) 19: 800-801 (Pubitemid 350011922)
47. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65
48. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102: 596-604
49. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S, Breed J (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19: 851-856 (Pubitemid 32119101)
50. Matsumoto S, Nishimura T, Kanai M, Ishiguro H, Yasuda H, Yoshikawa K, Misawa A, Kitano T, Yanagihara K, Fukushima M (2007) Development of a novel information technology (IT) system using the electronic medical record (EMR) in daily clinical practice (abstract). J Clin Oncol 25(Suppl 18S): 17066
51. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019
52. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20: 227-230
53. Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193 (Pubitemid 46178407)